Quantcast

Latest Actavis Stories

2014-01-31 08:24:53

- Realigns Existing Executive Team Expertise - DUBLIN, Jan. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced a realignment of its global strategic business structure to maximize the Company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. Under the new organizational structure, announced at Actavis' 2014 Investor Meeting in New York, Actavis' global...

2014-01-24 16:22:14

DUBLIN, Jan. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co., Ltd to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., Ltd., an Actavis subsidiary based in Foshan, China. Actavis intends to continue further commercial operations in China in collaboration with its preferred business partners. "Actavis is focused on strengthening our investment in high-growth...

2014-01-22 12:27:07

DUBLIN, Jan. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that its subsidiary, Watson Laboratories, Inc., has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Allergan, Inc.'s Restasis(®) (cyclosporine ophthalmic emulsion) 0.05% product. Actavis' ANDA was submitted prior to the issuance of FDA guidance related to approval of generic versions of Restasis(®)...

2014-01-18 00:20:27

DUBLIN, Jan. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to enter into an agreement for Aurobindo Pharma Limited (BSE: 524804) to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. Aurobindo would acquire Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium,...

2014-01-17 20:22:00

DUBLIN, Jan. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin(®) Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate...

2014-01-14 08:29:22

DUBLIN, Jan. 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, based on a preliminary review of 2013 results for the fourth quarter ended December 31, 2013, the Company expects non-GAAP earnings per diluted share for the fourth quarter 2013 to be modestly above the high end of its previous forecast. "2013 was a transformational year for Actavis, highlighted by the acquisition of Warner Chilcott plc and continued exceptional performance across our global...

2014-01-14 08:28:43

DUBLIN, Jan. 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced an updated business structure for its U.S. Specialty Brands business designed to maximize the Company's newly strengthened position in key therapeutic areas and position it for continued long-term growth. Under its new structure, Actavis' U.S. Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology...

2014-01-09 08:26:30

Revenue Growth of 12%-14% Expected Year-over-Year BOSTON, Jan. 9, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced preliminary, unaudited financial results of the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, the Company expects to report: -- Total revenues in the range of $7.4 to $8.0 million, as compared with $7.1 million in the fourth quarter of 2012. -- Services revenues from Molecular Profiles in the...

2014-01-08 16:26:48

DUBLIN, Jan. 8, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis(®). Actavis intends to launch the product immediately. As a "first applicant" to submit a substantially complete ANDA, Actavis is eligible for 180 days of...

2014-01-06 16:27:57

DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 31, 2014 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously. The meeting will be hosted by Actavis' executive leadership team and will provide an overview of executional results in 2013, initiatives to drive long-term growth and an in-depth look at the company following...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related